Bench-to-bedside review: β-Adrenergic modulation in sepsis

Critical Care

Volumn 13, Issue 5, 2009, Pages

  de Montmollin, Etienne ^a   Aboab, Jerome ^a   Mansart, Arnaud ^a   Annane, Djillali ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; HEMOSTASIS; HUMAN; IMMUNOMODULATION; METABOLIC DISORDER; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION; BLOOD CLOTTING DISORDER; CRITICAL ILLNESS; DISORDERS OF CARBOHYDRATE METABOLISM; HEART VENTRICLE FUNCTION; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; BLOOD COAGULATION DISORDERS; CRITICAL ILLNESS; GLUCOSE METABOLISM DISORDERS; HUMANS; SEPSIS; VENTRICULAR DYSFUNCTION;

EID: 77949890539     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8026     Document Type: Review

References (105)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
2. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003, 168:165-172. 10.1164/rccm.2201087, 12851245.
3. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891. 10.1038/nature01326, 12490963.
4. Oberbeck R, Kobbe P. Beta-adrenergic antagonists: indications and potential immunomodulatory side effects in the critically ill. Curr Med Chem 2009, 16:1082-1090. 10.2174/092986709787581770, 19275613.
5. Wallukat G. The beta-adrenergic receptors. Herz 2002, 27:683-690. 10.1007/s00059-002-2434-z, 12439640.
6. Zaugg M, Schaub MC, Pasch T, Spahn DR. Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. Br J Anaesth 2002, 88:101-123. 10.1093/bja/88.1.101, 11881864.
7. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
8. Santangelo S, Gamelli RL, Shankar R. Myeloid commitment shifts toward monocytopoiesis after thermal injury and sepsis. Ann Surg 2001, 233:97-106. 1421160, 11141231, 10.1097/00000658-200101000-00015.
9. Pinheiro da Silva F, Nizet V. Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection. Apoptosis 2009, 14:509-521. 10.1007/s10495-009-0320-3, 19199035.
10. Pinsky MR. Dysregulation of the immune response in severe sepsis. Am J Med Sci 2004, 328:220-229. 10.1097/00000441-200410000-00005, 15486537.
11. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000, 52:595-638.
12. Muthu K, Deng J, Romano F, He LK, Gamelli R, Shankar R, Jones SB. Thermal injury and sepsis modulates beta-adrenergic receptors and cAMP responses in monocyte-committed bone marrow cells. J Neuroimmunol 2005, 165:129-138. 10.1016/j.jneuroim.2005.04.015, 15955567.
13. Cohen MJ, Shankar R, Stevenson J, Fernandez R, Gamelli RL, Jones SB. Bone marrow norepinephrine mediates development of functionally different macrophages after thermal injury and sepsis. Ann Surg 2004, 240:132-141. 1356385, 15213629, 10.1097/01.sla.0000130724.84914.d6.
14. Oberbeck R. Catecholamines: physiological immunomodulators during health and illness. Curr Med Chem 2006, 13:1979-1989. 10.2174/092986706777584997, 16842192.
15. Oberbeck R, Schmitz D, Wilsenack K, Schuler M, Pehle B, Schedlowski M, Exton MS. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 2004, 11:214-223. 10.1159/000078439, 15249727.
16. Sekut L, Champion BR, Page K, Menius JA, Connolly KM. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995, 99:461-466. 1534196, 7882570.
17. Severn A, Rapson NT, Hunter CA, Liew FY. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol 1992, 148:3441-3445.
18. Muthu K, Deng J, Gamelli R, Shankar R, Jones SB. Adrenergic modulation of cytokine release in bone marrow progenitor-derived macrophage following polymicrobial sepsis. J Neuroimmunol 2005, 158:50-57. 10.1016/j.jneuroim.2004.08.003, 15589037.
19. Deng J, Muthu K, Gamelli R, Shankar R, Jones SB. Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. Am J Physiol Cell Physiol 2004, 287:C730-C736. 10.1152/ajpcell.00562.2003, 15151906.
20. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 1997, 158:4200-4210.
21. Ramer-Quinn DS, Baker RA, Sanders VM. Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production. J Immunol 1997, 159:4857-4867.
22. Bergmann M, Gornikiewicz A, Sautner T, Waldmann E, Weber T, Mittlbock M, Roth E, Fugger R. Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. Shock 1999, 12:421-427. 10.1097/00024382-199912000-00002, 10588509.
23. Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR, Schmidt RE. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol 1996, 156:93-99.
24. Schmitz D, Wilsenack K, Lendemanns S, Schedlowski M, Oberbeck R. β-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation 2007, 72:286-294. 10.1016/j.resuscitation.2006.07.001, 17118511.
25. Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Herndon DN. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma 2007, 62:676-681. 10.1097/TA.0b013e318031afd3, 17414346.
26. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, Takeda J. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005, 33:2294-2301. 10.1097/01.CCM.0000182796.11329.3B, 16215384.
27. Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultra-short-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock 2009, 31:515-520. 10.1097/SHK.0b013e3181863689, 18791493.
28. Boost KA, Flondor M, Hofstetter C, Platacis I, Stegewerth K, Hoegl S, Nguyen T, Muhl H, Zwissler B. The beta-adrenoceptor antagonist propranolol counteracts anti-inflammatory effects of isoflurane in rat endotoxemia. Acta Anaesthesiol Scand 2007, 51:900-908. 10.1111/j.1399-6576.2007.01363.x, 17635398.
29. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984, 100:483-490.
30. Court O, Kumar A, Parrillo JE. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002, 6:500-508. 153435, 12493071, 10.1186/cc1822.
31. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007, 35:1599-1608. 10.1097/01.CCM.0000266683.64081.02, 17452940.
32. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med 1997, 336:1131-1141. 10.1056/NEJM199704173361603, 9099657.
33. Feldman AM, Bristow MR. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology 1990, 77(Suppl 1):1-32. 10.1159/000174645, 1970755.
34. Romanosky AJ, Giaimo ME, Shepherd RE, Burns AH. The effect of in vivo endotoxin on myocardial function in vitro. Circ Shock 1986, 19:1-12.
35. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990, 82(2 Suppl):I12-I25.
36. Tang C, Yang J, Wu LL, Dong LW, Liu MS. Phosphorylation of beta-adrenergic receptor leads to its redistribution in rat heart during sepsis. Am J Physiol 1998, 274(4 Pt 2):R1078-R1086.
37. Matsuda N, Hattori Y, Akaishi Y, Suzuki Y, Kemmotsu O, Gando S. Impairment of cardiac beta-adrenoceptor cellular signaling by decreased expression of G(s alpha) in septic rabbits. Anesthesiology 2000, 93:1465-1473. 10.1097/00000542-200012000-00019, 11149442.
38. Brodde OE, Michel MC, Zerkowski HR. Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res 1995, 30:570-584.
39. Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000, 101:2338-2341.
40. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996, 17:354-381.
41. Pontet J, Contreras P, Curbelo A, Medina J, Noveri S, Bentancourt S, Migliaro ER. Heart rate variability as early marker of multiple organ dysfunction syndrome in septic patients. J Crit Care 2003, 18:156-163. 10.1016/j.jcrc.2003.08.005, 14595568.
42. Yien HW, Hseu SS, Lee LC, Kuo TB, Lee TY, Chan SH. Spectral analysis of systemic arterial pressure and heart rate signals as a prognostic tool for the prediction of patient outcome in the intensive care unit. Crit Care Med 1997, 25:258-266. 10.1097/00003246-199702000-00011, 9034261.
43. Gang Y, Malik M. Heart rate variability in critical care medicine. Curr Opin Crit Care 2002, 8:371-375. 10.1097/00075198-200210000-00002, 12357103.
44. Schmidt H, Muller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, Prondzinsky R, Loppnow H, Buerke M, Hoyer D, Werdan K. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 2005, 33:1994-2002. 10.1097/01.CCM.0000178181.91250.99, 16148471.
45. Korach M, Sharshar T, Jarrin I, Fouillot JP, Raphael JC, Gajdos P, Annane D. Cardiac variability in critically ill adults: influence of sepsis. Crit Care Med 2001, 29:1380-1385. 10.1097/00003246-200107000-00013, 11445691.
46. Godin PJ, Fleisher LA, Eidsath A, Vandivier RW, Preas HL, Banks SM, Buchman TG, Suffredini AF. Experimental human endotoxemia increases cardiac regularity: results from a prospective, randomized, crossover trial. Crit Care Med 1996, 24:1117-1124. 10.1097/00003246-199607000-00009, 8674322.
47. Goldstein B, Kempski MH, Stair D, Tipton RB, DeKing D, DeLong DJ, DeAsla R, Cox C, Lund N, Woolf PD. Autonomic modulation of heart rate variability during endotoxin shock in rabbits. Crit Care Med 1995, 23:1694-1702. 10.1097/00003246-199510000-00014, 7587235.
48. Annane D, Trabold F, Sharshar T, Jarrin I, Blanc AS, Raphael JC, Gajdos P. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 1999, 160:458-465.
49. Berk JL, Hagen JF, Beyer WH, Gerber MJ, Dochat GR. The treatment of endotoxin shock by beta adrenergic blockade. Ann Surg 1969, 169:74-81. 1387267, 4883485, 10.1097/00000658-196901000-00007.
50. Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg 1972, 104:46-51.
51. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994, 330:1717-1722. 10.1056/NEJM199406163302404, 7993413.
52. Patterson AJ, Zhu W, Chow A, Agrawal R, Kosek J, Xiao RP, Kobilka B. Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart. Crit Care Med 2004, 32:1041-1048. 10.1097/01.CCM.0000120049.43113.90, 15071399.
53. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006, 139:686-694. 10.1016/j.surg.2005.10.010, 16701103.
54. Schmittinger CA, Dunser MW, Haller M, Ulmer H, Luckner G, Torgersen C, Jochberger S, Hasibeder WR. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008, 12:R99. 2575588, 18680591, 10.1186/cc6976.
55. Niemela MJ, Airaksinen KE, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994, 23:1370-1377.
56. Aronson D, Burger AJ. Effect of beta-blockade on heart rate variability in decompensated heart failure. Int J Cardiol 2001, 79:31-39. 10.1016/S0167-5273(01)00401-6, 11399339.
57. Lin LY, Lin JL, Du CC, Lai LP, Tseng YZ, Huang SK. Reversal of deteriorated fractal behavior of heart rate variability by beta-blocker therapy in patients with advanced congestive heart failure. J Cardiovasc Electrophysiol 2001, 12:26-32. 10.1046/j.1540-8167.2001.00026.x, 11204080.
58. Trager K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 2003, 9:271-278. 10.1097/00075198-200308000-00004, 12883281.
59. Chiolero R, Revelly JP, Tappy L. Energy metabolism in sepsis and injury. Nutrition 1997, 13(9 Suppl):45S-51S. 10.1016/S0899-9007(97)00205-0, 9290109.
60. Hasselgren PO. Catabolic response to stress and injury: implications for regulation. World J Surg 2000, 24:1452-1459. 10.1007/s002680010262, 11193708.
61. Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367. 10.1056/NEJMoa011300, 11794168.
62. Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 2003, 31:359-366. 10.1097/01.CCM.0000045568.12881.10, 12576937.
63. Brierre S, Kumari R, Deboisblanc BP. The endocrine system during sepsis. Am J Med Sci 2004, 328:238-247. 10.1097/00000441-200410000-00007, 15486539.
64. Chambrier C, Laville M, Rhzioual Berrada K, Odeon M, Bouletreau P, Beylot M. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci (Lond) 2000, 99:321-328. 10.1042/CS20000017, 10995598.
65. Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab 2007, 293:E453-E459. 10.1152/ajpendo.00204.2007, 17505052.
66. Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr 2006, 136(1 Suppl):227S-231S.
67. Lang CH, Frost RA. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle. J Cell Physiol 2005, 203:144-155. 10.1002/jcp.20207, 15389631.
68. Fink MP. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin 2001, 17:219-237. 10.1016/S0749-0704(05)70161-5, 11219231.
69. Fink MP. Bench-to-bedside review: Cytopathic hypoxia. Crit Care 2002, 6:491-499. 153437, 12493070, 10.1186/cc1824.
70. John GW, Doxey JC, Walter DS, Reid JL. The role of alpha- and beta-adrenoceptor subtypes in mediating the effects of catecholamines on fasting glucose and insulin concentrations in the rat. Br J Pharmacol 1990, 100:699-704. 1917573, 1976400.
71. Haffner CA, Kendall MJ. Metabolic effects of beta 2-agonists. J Clin Pharm Ther 1992, 17:155-164.
72. Lang CH. Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. Am J Physiol 1992, 263(4 Pt 1):E703-E711.
73. McGuinness OP, Shau V, Benson EM, Lewis M, Snowden RT, Greene JE, Neal DW, Cherrington AD. Role of epinephrine and norepinephrine in the metabolic response to stress hormone infusion in the conscious dog. Am J Physiol 1997, 273(4 Pt 1):E674-E681.
74. Trager K, Radermacher P, Debacker D, Vogt J, Jakob S, Ensinger H. Metabolic effects of vasoactive agents. Curr Opin Anaesthesiol 2001, 14:157-163. 10.1097/00001503-200104000-00006, 17016396.
75. Levy B, Mansart A, Bollaert PE, Franck P, Mallie JP. Effects of epinephrine and norepinephrine on hemodynamics, oxidative metabolism, and organ energetics in endotoxemic rats. Intensive Care Med 2003, 29:292-300.
76. Dahn MS, Lange P, Lobdell K, Hans B, Jacobs LA, Mitchell RA. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery 1987, 101:69-80.
77. Ensinger H, Trager K, Geisser W, Anhaupl T, Ahnefeld FW, Vogt J, Georgieff M. Glucose and urea production and leucine, ketoisocaproate and alanine fluxes at supraphysiological plasma adrenaline concentrations in volunteers. Intensive Care Med 1994, 20:113-118. 10.1007/BF01707665, 8201090.
78. De Backer D, Creteur J, Noordally O, Smail N, Gulbis B, Vincent JL. Does hepatosplanchnic VO2/DO2 dependency exist in critically ill septic patients?. Am J Respir Crit Care Med 1998, 157(4 Pt 1):1219-1225.
79. Asfar P, De Backer D, Meier-Hellmann A, Radermacher P, Sakka SG. Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock. Crit Care 2004, 8:170-179. 468887, 15153235, 10.1186/cc2418.
80. Matthews DE, Pesola G, Campbell RG. Effect of epinephrine on amino acid and energy metabolism in humans. Am J Physiol 1990, 258(6 Pt 1):E948-E956.
81. Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: propranolol. Crit Care Med 2007, 35(9 Suppl):S616-S620. 10.1097/01.CCM.0000278599.30298.80, 17713418.
82. Hargrove DM, Bagby GJ, Lang CH, Spitzer JJ. Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism. Am J Physiol 1988, 255(5 Pt 1):E629-E635.
83. Dickerson RN, Fried RC, Bailey PM, Stein TP, Mullen JL, Buzby GP. Effect of propranolol on nitrogen and energy metabolism in sepsis. J Surg Res 1990, 48:38-41. 10.1016/0022-4804(90)90142-O, 2104945.
84. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001, 345:1223-1229. 10.1056/NEJMoa010342, 11680441.
85. Ichihara S, Yamada Y, Ichihara G, Kanazawa H, Hashimoto K, Kato Y, Matsushita A, Oikawa S, Yokota M, Iwase M. Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun 2006, 350:105-113. 10.1016/j.bbrc.2006.09.026, 16997276.
86. Caruana JA, Whalen DA, Maben WC, Chen HH. Beta-adrenergic blockade increases the hepatic extraction of glucose in sepsis. Arch Surg 1986, 121:319-323.
87. Vincent JL, Yagushi A, Pradier O. Platelet function in sepsis. Crit Care Med 2002, 30(5 Suppl):S313-S317. 10.1097/00003246-200205001-00022, 12004253.
88. Boldt J, Menges T, Wollbruck M, Sonneborn S, Hempelmann G. Platelet function in critically ill patients. Chest 1994, 106:899-903. 10.1378/chest.106.3.899, 8082375.
89. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997, 23:379-385. 10.1007/s001340050344, 9142575.
90. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000, 28:451-457. 10.1097/00003246-200002000-00027, 10708182.
91. Hjemdahl P, Larsson PT, Wallen NH. Effects of stress and beta-blockade on platelet function. Circulation 1991, 84(6 Suppl):VI44-VI61.
92. von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol 2000, 65:357-369. 10.1034/j.1600-0609.2000.065006357.x, 11168493.
93. Schwencke C, Schmeisser A, Weinbrenner C, Braun-Dullaeus RC, Marquetant R, Strasser RH. Transregulation of the alpha2-adrenergic signal transduction pathway by chronic beta-blockade: a novel mechanism for decreased platelet aggregation in patients. J Cardiovasc Pharmacol 2005, 45:253-259. 10.1097/01.fjc.0000154372.03531.e1, 15725951.
94. Markel A, Brook JG, Levy Y, Aviram M, Youdim MB. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. Br J Clin Pharmacol 1983, 16:663-668. 1428341, 6661351.
95. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004, 30:1032-1040. 10.1007/s00134-004-2291-8, 15148567.
96. Schouten M, Wiersinga WJ, Levi M, Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008, 83:536-545. 10.1189/jlb.0607373, 18032692.
97. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005, 23:821-852. 10.1146/annurev.immunol.23.021704.115835, 15771587.
98. Laudes IJ, Chu JC, Sikranth S, Huber-Lang M, Guo RF, Riedemann N, Sarma JV, Schmaier AH, Ward PA. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002, 160:1867-1875. 1850866, 12000738.
99. Gader AM, Da Costa J, Cash JD. The effect propranolol, alprenolol and practolol on the vibrinolytic and factor VIII responses to adrenaline and salbutamol in man. Thromb Res 1974, 4:25-33. 10.1016/0049-3848(74)90201-1, 4829668.
100. von Kanel R, Dimsdale JE, Adler KA, Dillon E, Perez CJ, Mills PJ. Effects of nonspecific beta-adrenergic stimulation and blockade on blood coagulation in hypertension. J Appl Physiol 2003, 94:1455-1459.
101. Osterud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis 1995, 6(Suppl 1):S20-S25. 10.1097/00001721-199506001-00004, 7544163.
102. Ogston D, Mc DG, Fullerton HW. The influence of anxiety in tests of blood coagulability and fibrinolytic activity. Lancet 1962, 2(7255):521-523. 10.1016/S0140-6736(62)90398-7, 14481318.
103. Teger-Nilsson AC, Larsson PT, Hjemdahl P, Olsson G. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade. Circulation 1991, 84(6 Suppl):VI72-VI77.
104. Adler B, Gimbrone MA, Schafer AI, Handin RI. Prostacyclin and beta-adrenergic catecholamines inhibit arachidonate release and PGI2 synthesis by vascular endothelium. Blood 1981, 58:514-517.
105. Loegering DJ, Commins LM. Effect of beta-receptor stimulation on Kupffer cell complement receptor clearance function. Circ Shock 1988, 25:325-332.